


An Innovator and Developer of OPMD & Early Cancer Diagnostics



Our Mission

To **save lives** by providing world-class **early detection** solutions for cancer and OPMD

Our First Early Cancer Detection Product

The **BeVigilant™ OraFusion™ System** aids clinicians with identifying patients at risk for **oral cancer**.


Current State of Oral Cancer – The Problem

- 700,000+ new cases globally per year
- Projected to be 3rd most prevalent cancer among men in US in 20 years
- * >73% of cases diagnosed late-stage
- 5-year survival rate: <50%
- Survival rate early-stage >80%
- Mis-diagnosis #2 reason Dentist get sued (avg settlement >\$2.5M)

Key Point:

The current standard needs to be improved. The dental industry needs a tool to help!

M.D. Anderson Cancer Center Report




* *Vigilant is trying to solve this problem!*


Oral Cancer is an Indiscriminate Disease



Ulysses S. Grant, 1884



Grover Cleveland, 1893



Sigmund Freud, 1923



Jim Thorpe, 1950



Humphrey Bogart, 1956



Ed Sullivan, 1974



Sammy Davis, Jr., 1989



Lana Turner, 1992



Bill Tuttle, 1993




Diane von Furstenburg, 1994



Brett Butler, 1996



George Harrison, 1998



Rene Angelil, 1999



Rod Stewart, 2000



Eddie Van Halen, 2000



Aaron Spelling, 2001




Roger Ebert, 2002



Hubert Green, 2003



Susan Buffett, 2003



Hank Ballard, 2003



Colleen Zenk, 2007



Michael Douglas, 2010



Larry Hagman, 2011



Jim Kelly, 2013



Michael Cooper, 2014



Jamie Dimon, 2014



Val Kilmer, 2015



Erin Moran, 2016



Stanley Tucci, 2017



Dick Vitale, 2022


Current Standard of Care – Oral Visual Exam

- Oral cancer screening
 - Performed by Dentist / Hygienist
 - Looking for signs of cancer or precancer
 - ~29% patients have an oral abnormality**
- ADA recommends every visit on every patient
- Dentist's is responsible and liable to detect oral abnormalities, diagnosing and referring patients
- Accuracy: ~50/50**

Key Point:




Visual Exam is not enough to accurately detect early-stage cancer



8 STEPS OF **ORAL CANCER SCREENING**

Current Standard Clinical Workflow



The current process only works when the lesion is obviously suspicious ... late-stage cancers!

Results:
>73% diagnosed late-stage
< 50% survival Rate

***Current Key Decision**

Visual Exam - Examples



- Diagnosis:
- TRAUMATIC ULCER



- Diagnosis:
- EARLY SQUAMOUS CELL CARCINOMA

Visual Exam - Examples



- Diagnosis:
- EARLY SQUAMOUS CELL CARCINOMA



- Diagnosis:
- EARLY SQUAMOUS CELL CARCINOMA

The BeVigilant™ OraFusion™ Platform

First-of-its-kind risk assessment / diagnostic device provides exceptional accuracy



Intelligent software
for clinical risk
factor assessment



Ora-3D™ lateral flow
immunoassay with
multiple proprietary
biomarkers

Whole saliva disposable
collection device

The OraFusion™ System is designed for use with small amounts (<1 ml) of whole fresh saliva.


How it Works – Fusion of Information

- Biomarkers in Saliva (major contributor)
 - Exact concentrations
 - Relationship to each other
 - How they are affected by other factors (such as age)
- Clinical Risk Factors (minor contributor)
 - Age, Gender, Tobacco and Alcohol
- AI / ML Algorithm driven
- Simple, actionable results
- Extremely accurate
 - Se, Sp, NPV ~93%

Key Point:



Accuracy improves with the fusion of results ... 1 + 1 = 3




Progression of an Oral Abnormality to Oral Cancer

- Over 3000 proteomic & peptide biomarkers naturally exist in saliva
- As a lesion starts to exhibit cancerous behavior – biomarkers become overexpressed
- Identifying the concentrations of these biomarkers assist in the early detection
- Vigilant identified two proteomic biomarkers present in early stages



Key Point:

Precise biomarker concentration detection is essential to early diagnosis



Elevated risk of Cancer

CONFIDENTIAL & PROPRIETARY

The Future of Early Cancer Detection

Multifactorial Oral Cancer Risk Stratification

Intervention & Assessment


Health Economics




- Population studies
- Identify risk factors
- Algorithm development



- Advanced Data Analysis
- Early-Stage Detection
- Likelihood of Cancer
- Simple Personalized Output
 - Low/Mod/Elevated
- Software Implemented Algorithm
- Improved Screening



- Improved High Risk Surveillance
- Specialized Treatment Plans
- Better Outcomes
 - Uptake of Risk Assessments
 - Uptake of Screening
 - Acceptance with Knowledge



Harm vs Benefit

Pre-Diagnostic
(Risk Assessment)

Diagnostics

Benefit to General Dentist

When to Use the OraFusion Test


- Oral Potentially Malignant Disorders (OPMD) could lead to oral cancer and should all be tested
- Dentist face the decision on how to treat these disorders on a regular basis
- Liability for diagnosis occurs from the moment the patient enters the practice

Key Point:




All OPMDs should be tested to prevent late-stage diagnosis

Risk Factors & OPMD




*NIH: Oral Potentially Malignant Disorders, Pratima Kumari; Priyanka Debta; Anshuman Dixit

Recommended Clinical Workflow for OraFusion Test



Clinical Study Results – *FDA Pending*

A dramatic improvement in clinician's ability to properly assess patients for risk of oral cancer



“Essentially doubling my accuracy in properly assessing patients for oral cancer is amazing!”

Dr. Thomas, Orlando FL (Dental Panel member)

Benefits to Dentists – Make them the Hero ... Save a life

- Accurately assess patients
 - Unlikely cancerous behavior – **Peace of Mind**
 - Likely cancer or precancer – **Sense of Urgency**
- Objective evidence that clinician should take action – **Escalate Care**
- Increase Patient follow through
 - Follow up with Specialist – Get a biopsy
- Decrease Liability
 - Reduce malpractice risk of mis-diagnosis

Keys to Patient Communication:

- Elevate the status of the practice
 - Health care provided
 - Concern for patient's well being
- Clinician does not have to tell the patient they have cancer (that comes from biopsy)
 - Objective measure of “suspicious” abnormality
 - Need to escalate care
 - A specialist can rule out biggest concern
 - *Odds have it, it's nothing, but what if it's something!*
- **Catch the problem *Early*, before it's too late**

Get Checked ... BeVigilant™